As of 6 Nov 2026, Zim Laboratories trades at 160.6× trailing earnings, above the industry P/E of 28.7×, and the shares are 18% below their 52-week high. Sales and net profit fell 2.5% and 38% a year over 3 years; its ROCE of 5.8% is the lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. Debt is 0.52× equity. It is a small-cap company with a market cap of ₹705 Cr, ranked 77th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 88% over the past year.
- ₹133.55
- ₹135.63
- ₹131.01
- ₹136.94
- 54.8K
Health check
- ReturnsAhead
+87.9% over a year, better than 6 of 7 peers.
- Price tagPricier
P/E 160.6 vs industry 28.7.
- GrowthShrinking
Sales −2.5%, profit −37.9% a year over 3 years.
- ProfitabilityWeak
ROCE 5.8% vs peer median 17.9%.
- Balance sheetFair
Debt 0.52× equity, interest covered 1.7×, Piotroski 6 of 9.
- Red flags4 to check
Return on equity is low at 0.8%.
Small cap
Market sensitivity
Key metrics
- Market cap
- ₹705 Cr
- Small cap
- P/E
- 160.6
- Industry 28.7
- Price to book
- 2.43
- Peers 4.99
- Dividend yield
- 0.00%
- ROE
- 0.8%
- Peers 14.7%
- ROCE
- 5.8%
- Peers 17.9%
- Debt to equity
- 0.52
- Debt ₹151 Cr
- EPS (TTM)
- ₹0.82
- Face value ₹10
- OPM (TTM)
- 7.1%
- Net margin 0.5%
- Sales growth
- +31.2%
- Latest quarter vs a year ago
- Profit growth
- n/a
- Year-ago quarter not reported
- Price to sales
- 1.71
- EV/EBITDA 37.3
Strengths and risks
Strengths
- Quarterly sales up 31.2% on a year ago.
- Positive operating cash flow in each of the last 4 years.
Risks to check
- Return on equity is low at 0.8%.
- P/E of 160.6 against an industry P/E of 28.7.
- Interest coverage of only 2.6×.
- Promoter stake down from 33.3% to 30.3%.
About Zim Laboratories
ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, directly compressible granules, tablets, capsules, dry syrup, and oral thin films. The company offers therapeutics in the areas of urology,…
- Headquarters
- Nagpur
- Employees
- 632
- Sector
- Healthcare
- ISIN
- INE518E01015
- Website
- zimlab.in
Price range
- Avg volume (3M)
- 1.4 L
- 1-year return
- plus 87.9%
- From 52-week high
- minus 17.6%
Peers · Drug Manufacturers - Specialty & Generic
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | 1,860.00 | plus 1.69% | 4,46,276 | 40.7 | 4.99 | 17.9% | 13.1% | 28.2% | 10.4% | 10.6% | 0.86% | plus 8.2% |
| DIVISLABDivi's Laboratories | 10,320.50 | plus 1.78% | 2,73,977 | 93.6 | 16.35 | 19.0% | 16.2% | 34.9% | 11.0% | 12.1% | 0.29% | plus 49.0% |
| TORNTPHARMTorrent Pharmaceuticals | 4,750.00 | plus 0.85% | 1,80,675 | 80.2 | 9.83 | 9.1% | 15.7% | 33.7% | 13.3% | 20.2% | 0.80% | plus 31.7% |
| LAURUSLABSLaurus Labs | 2,340.00 | minus 0.26% | 1,26,433 | 94.4 | 20.86 | 19.5% | 24.0% | 30.4% | 3.8% | 4.0% | 0.09% | plus 138.6% |
| ZYDUSLIFEZydus Lifesciences | 1,197.90 | plus 0.41% | 1,19,491 | 28.6 | 4.29 | 19.0% | 14.7% | 26.2% | 16.5% | 37.0% | 0.08% | plus 22.8% |
| DRREDDYDr. Reddy's Laboratories | 1,373.00 | plus 0.51% | 1,14,462 | 40.9 | 2.96 | 14.2% | 7.3% | 15.9% | 11.0% | −1.7% | 0.58% | plus 13.8% |
| CIPLACipla | 1,411.00 | plus 0.49% | 1,13,993 | 39.4 | 3.22 | 14.9% | 8.3% | 17.3% | 7.2% | 11.5% | 0.92% | minus 6.6% |
| ZIMLABZim Laboratories | 131.67 | minus 3.85% | 705 | 160.6 | 2.43 | 5.8% | 2.1% | 7.1% | −2.5% | −37.9% | 0.00% | plus 87.9% |
| Median of 7 peers | – | 0.51% | 1,26,433 | 40.9 | 4.99 | 17.9% | 14.7% | 28.2% | 11.0% | 11.5% | 0.58% | 22.8% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 71.8 | 88.7 | 109 | 105 | 94.2 | |
| 67.5 | 83 | 95.9 | 98.1 | 91.7 | |
| 4.3 | 5.8 | 12.8 | 7.2 | 2.5 | |
| 5.9% | 6.5% | 11.8% | 6.8% | 2.6% | |
| 1.5 | 2 | 1.7 | 6.2 | 1 | |
| 3.3 | 3.2 | 3.4 | 3.3 | 3.6 | |
| 4.9 | 5 | 5 | 5.1 | 5.4 | |
| −2.4 | −0.3 | 6 | 4.9 | −5.6 | |
| 22.9% | −23.5% | 27.3% | 24.3% | 27.9% | |
| −1.9 | −0.4 | 4.4 | 3.7 | −4 | |
| -0.38 | -0.09 | 0.90 | 0.76 | -0.75 |
Profit & loss
- Sales CAGR 3Y
- −2.5%
- Profit CAGR 3Y
- −37.9%
- EPS CAGR 3Y
- −38.1%
- ROE
- 0.8%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 389 | 356 | 363 | 360 | |
| – | minus 8.5% | +2.1% | minus 0.8% | |
| 336 | 313 | 316 | 329 | |
| 52.7 | 42.7 | 46.7 | 31.1 | |
| 13.6% | 12.0% | 12.9% | 8.6% | |
| 5.7 | 3.9 | 3.6 | 7.5 | |
| 5 | 5.9 | 10.2 | 12.1 | |
| 17.5 | 16 | 20.1 | 20 | |
| −0.7 | −1.1 | −1.9 | 1.7 | |
| 35.4 | 23.6 | 18 | 8.2 | |
| 30.9% | 27.1% | 32.5% | 28.9% | |
| 24.4 | 17.2 | 12.2 | 5.8 | |
| – | minus 29.4% | minus 29.5% | minus 52.0% | |
| 5.01 | 3.54 | 2.50 | 1.19 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 48.7 | 48.7 | 48.7 | 53.5 | |
| 152 | 190 | 204 | 243 | |
| 62 | 112 | 118 | 126 | |
| 79.2 | 96.4 | 102 | 117 | |
| 342 | 447 | 472 | 539 | |
| 122 | 180 | 202 | 215 | |
| 17.8 | 23.5 | 44.1 | 58.8 | |
| 0.1 | 0.1 | 0.1 | 0.1 | |
| 6.5 | 9.6 | 1.9 | 27.8 | |
| 196 | 233 | 224 | 238 | |
| 342 | 447 | 472 | 539 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 38.2 | 16.3 | 41.2 | 49.5 | |
| −36.2 | −73 | −39.9 | −56.3 | |
| 0.5 | 59.5 | −9.1 | 28.2 | |
| 2.5 | 2.8 | −7.9 | 21.4 | |
| −36.7 | −73.9 | −40.8 | −44.4 | |
| 1.5 | −57.6 | 0.4 | 5.1 | |
| −0.1 | −0 | −0.1 | −0.1 |
Shareholding pattern
- Promoters30.30%
- Public69.70%
| Quarter | Split | Promoters | Public | Promoter change |
|---|---|---|---|---|
| 30 Sep 2026 | 30.30% | 69.70% | minus 0.06 | |
| 30 Jun 2026 | 30.36% | 69.64% | plus 0.01 | |
| 31 Mar 2026 | 30.35% | 69.65% | plus 0.05 | |
| 13 Mar 2026 | 30.30% | 69.70% | minus 2.96 | |
| 31 Dec 2025 | 33.26% | 66.74% | – |
Major shareholders
Filings & events
News
No recent news coverage found.